Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilberto Lopes

Showing results (11-20 of 177) with videos related to

Pageof 18
Sort By:
JCO Global Oncology|June 17, 2022
Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?Joydeep Ghosh, Gilberto Lopes, Surpiya Chopra
Pharmacotherapy|March 1, 2006
Dipyrone-induced granulocytopenia: a case for awarenessSantiago Garcia, Mariana Canionero, Gilberto Lopes
JCO Global Oncology|June 2, 2021
COVID-19 and Global Oncology: A Year in ReviewAakash Desai, Narjust Duma, Gilberto Lopes
American Journal of Clinical Oncology|January 20, 2023
The Effect of Biomarkers on Clinical Trial Risk in Gastric CancerSumeet Dhillon, Gilberto Lopes, Jayson L Parker
Lung Cancer (Amsterdam, Netherlands)|December 20, 2005
Pemetrexed-associated urticarial vasculitisGilberto Lopes, Vladimir Vincek, Luis E Raez
Seminars in Oncology|July 15, 2005
Docetaxel in the management of advanced pancreatic cancerGilberto Lopes, Caio Max S Rocha Lima
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancerLuis E Raez, Gilberto Lopes, Rogerio Lilenbaum
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancerAdam Falconi, Gilberto Lopes, Jayson L Parker
Pharmacoeconomics - Open|July 22, 2021
Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer PerspectiveNan Qiao, Ralph Insinga, Thomas Burke, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 5, 2007
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer InstituteChristopher Lobo, Gilberto Lopes, Orlando Silva, et al.
Pageof 18

Showing results (11-20 of 177) with videos related to

Sort By:
Pageof 18
JCO Global Oncology|June 17, 2022
Are We Right on Target? Is Comprehensive Genomic Profiling Ready for Prime Time in Resource-Constrained Settings?Joydeep Ghosh, Gilberto Lopes, Surpiya Chopra
Pharmacotherapy|March 1, 2006
Dipyrone-induced granulocytopenia: a case for awarenessSantiago Garcia, Mariana Canionero, Gilberto Lopes
JCO Global Oncology|June 2, 2021
COVID-19 and Global Oncology: A Year in ReviewAakash Desai, Narjust Duma, Gilberto Lopes
American Journal of Clinical Oncology|January 20, 2023
The Effect of Biomarkers on Clinical Trial Risk in Gastric CancerSumeet Dhillon, Gilberto Lopes, Jayson L Parker
Lung Cancer (Amsterdam, Netherlands)|December 20, 2005
Pemetrexed-associated urticarial vasculitisGilberto Lopes, Vladimir Vincek, Luis E Raez
Seminars in Oncology|July 15, 2005
Docetaxel in the management of advanced pancreatic cancerGilberto Lopes, Caio Max S Rocha Lima
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2005
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancerLuis E Raez, Gilberto Lopes, Rogerio Lilenbaum
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 15, 2014
Biomarkers and receptor targeted therapies reduce clinical trial risk in non-small-cell lung cancerAdam Falconi, Gilberto Lopes, Jayson L Parker
Pharmacoeconomics - Open|July 22, 2021
Cost-Minimization Analysis of Pembrolizumab Monotherapy Versus Nivolumab in Combination with Ipilimumab as First-Line Treatment for Metastatic PD-L1-Positive Non-small Cell Lung Cancer: A US Payer PerspectiveNan Qiao, Ralph Insinga, Thomas Burke, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 5, 2007
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer InstituteChristopher Lobo, Gilberto Lopes, Orlando Silva, et al.
Pageof 18